{"title": "Prone positioning under VV-ECMO in SARS-CoV-2-induced acute respiratory distress syndrome", "pubDate": "2020", "PMCID": "PMC7358559", "DOI": "10.1186/s13054-020-03162-4", "PMID": "32665007", "abstract": "", "author": [{"author": "Bruno Garcia", "affiliation": ["CHU Lille, P\u00f4le de r\u00e9animation, F-59000, Lille, France."], "href": "/?term=Garcia+B&cauthor_id=32665007"}, {"author": "Nicolas Cousin", "affiliation": ["CHU Lille, P\u00f4le de r\u00e9animation, F-59000, Lille, France."], "href": "/?term=Cousin+N&cauthor_id=32665007"}, {"author": "Claire Bourel", "affiliation": ["CHU Lille, P\u00f4le de r\u00e9animation, F-59000, Lille, France."], "href": "/?term=Bourel+C&cauthor_id=32665007"}, {"author": "Merc\u00e9 Jourdain", "affiliation": ["CHU Lille, P\u00f4le de r\u00e9animation, F-59000, Lille, France.", "Univ. Lille, Inserm Pasteur Lille, Inserm U1190 EGID, F-59000, Lille, France."], "href": "/?term=Jourdain+M&cauthor_id=32665007"}, {"author": "Julien Poissy", "affiliation": ["CHU Lille, P\u00f4le de r\u00e9animation, F-59000, Lille, France.", "Univ. Lille, Inserm U1285, CNRS, UMR 8576 - Unit\u00e9 de Glycobiologie Structurale et Fonctionnelle, F-59000, Lille, France."], "href": "/?term=Poissy+J&cauthor_id=32665007"}, {"author": "Thibault Duburcq", "affiliation": ["CHU Lille, P\u00f4le de r\u00e9animation, F-59000, Lille, France. thibault.duburcq@chru-lille.fr."], "href": "/?term=Duburcq+T&cauthor_id=32665007"}, {"author": "Lille Intensive Care COVID-19 group", "affiliation": [], "href": "/?term=Lille+Intensive+Care+COVID-19+group%5BCorporate+Author%5D"}, {"author": "Pauline Boddaert", "affiliation": [], "href": "/?term=Boddaert+P"}, {"author": "Arthur Durand", "affiliation": [], "href": "/?term=Durand+A"}, {"author": "Ahmed El Kalioubie", "affiliation": [], "href": "/?term=El+Kalioubie+A"}, {"author": "Patrick Girardie", "affiliation": [], "href": "/?term=Girardie+P"}, {"author": "Marion Houard", "affiliation": [], "href": "/?term=Houard+M"}, {"author": "Geoffrey Ledoux", "affiliation": [], "href": "/?term=Ledoux+G"}, {"author": "Anne Sophie Moreau", "affiliation": [], "href": "/?term=Moreau+AS"}, {"author": "Christopher Niles", "affiliation": [], "href": "/?term=Niles+C"}, {"author": "Saad Nseir", "affiliation": [], "href": "/?term=Nseir+S"}, {"author": "Thierry Onimus", "affiliation": [], "href": "/?term=Onimus+T"}, {"author": "Aurelia Toussaint", "affiliation": [], "href": "/?term=Toussaint+A"}, {"author": "Sebastien Pr\u00e9au", "affiliation": [], "href": "/?term=Pr%C3%A9au+S"}, {"author": "Laurent Robriquet", "affiliation": [], "href": "/?term=Robriquet+L"}, {"author": "Anahita Rouze", "affiliation": [], "href": "/?term=Rouze+A"}, {"author": "Arthur Simonnet", "affiliation": [], "href": "/?term=Simonnet+A"}, {"author": "Sophie Six", "affiliation": [], "href": "/?term=Six+S"}, {"author": "Morgan Caplan", "affiliation": [], "href": "/?term=Caplan+M"}, {"author": "Julien Goutay", "affiliation": [], "href": "/?term=Goutay+J"}, {"author": "Emmanuelle Jaillette", "affiliation": [], "href": "/?term=Jaillette+E"}, {"author": "Erika Parmentier-Decrucq", "affiliation": [], "href": "/?term=Parmentier-Decrucq+E"}, {"author": "Raphael Favory", "affiliation": [], "href": "/?term=Favory+R"}, {"author": "Daniel Mathieu", "affiliation": [], "href": "/?term=Mathieu+D"}, {"author": "Guillaume Degouy", "affiliation": [], "href": "/?term=Degouy+G"}, {"author": "Mouhamed Moussa", "affiliation": [], "href": "/?term=Moussa+M"}], "refPMID": ["32299472", "26538308", "31197492", "32191764", "32328726", "32293518"], "citedInPMID": ["32665007", "35111786", "35037993", "34986895", "34778984", "34582415", "34497744", "34461971", "34384475", "34197349", "33822952", "33820904", "33670987", "33646078", "33354678"], "body": " BackgroundInfection due to severe acute respiratory coronavirus 2 (SARS-CoV-2) may lead to an atypical acute respiratory distress syndrome (ARDS) [1], requiring in the most severe cases veno-venous extracorporeal membrane oxygenation (VV-ECMO). The management of persistent severe hypoxemia under VV-ECMO requires a multi-step clinical approach including prone positioning (PP), which could improve oxygenation [2]. MethodsWe performed a retrospective study of patients with SARS-CoV-2-induced ARDS submitted to PP during VV-ECMO. We aimed to describe mechanical ventilation parameters and gas exchanges before and after PP. We assess the safety of PP and compare patients with PP under ECMO (prone ECMO group) to those maintained in the supine position (supine ECMO group). Patients were treated in accordance with the recommendation guidelines on ARDS [3]. During VV-ECMO, PP was considered in case of severe hypoxemia (PaO2/FiO2 ratio below 80\u2009mmHg) despite FDO2 and FiO2 both at 100% and in case of extensive lung consolidation (ECL) on chest imaging (>\u200950% of lung volume). ResultsWe enrolled 208 COVID-19 patients. Among the 125 patients with ARDS, 25 (20%) required VV-ECMO, and 14 (56%) were placed at least once in PP for a total of 24 procedures with a median duration of 16 (15\u201317) h. The delay from ECMO implantation therapy to PP was 1.5\u00a0days [1\u20133]. The resultant changes in ventilator/ECMO settings and blood gas analysis before and after PP are displayed in Table\u00a01. The median PaO2/FiO2 ratio improvement after PP was 28% [2\u201336]. High responders (increase PaO2/FiO2 ratio >\u200920%) were 62.5%, moderate-responders (increase PaO2/FiO2 <\u200920%) were 16.7%, and non-responders (decrease PaO2/FiO2) were 20.8%. We did not observe any major safety concerns but only pressure sores after 6 procedures, three minor hemorrhages at the injection cannula, and three moderate drops in VV-ECMO flow requiring fluid resuscitation. Pre-ECMO characteristics, ventilator/ECMO settings, and outcomes are exposed in Table\u00a02. Patients in the prone ECMO group were less likely to be weaned from ECMO, and 28-day mortality rate was significantly higher.\nTable 1The resultant changes in ventilator/ECMO settings and blood gas analysis before and after PPVariablesBefore prone positionAfter prone positionP valueMechanical ventilation settings\u2003Tidal volume (mL/kg)2.4 (1.8\u20132.9)2.4 (1.8\u20132.7)0.42\u2003RR (breaths/min)20 (16\u201325)19 (16\u201325)0.87\u2003Plateau airway pressure (cmH2O)28 (26\u201332)29 (28\u201332)0.43\u2003PEEP (cmH2O)14 (12\u201318)16 (12\u201320)0.36\u2003Respiratory system compliance (mL/cmH2O)18.6 (13.7\u201325.9)17.9 (12.8\u201326.5)0.92\u2003Driving pressure (cmH2O)14.5 (12\u201316.5)14.5 (11\u201316)0.56\u2003Inspired fraction of oxygen (%)70 (60\u2013100)67.5 (52.5\u201395)0.16ECMO settings\u2003ECMO blood flow (L/min)6.2 (6\u20136.7)6 (5.8\u20136.7)0.41\u2003Sweep gas flow (L/min)7 (6\u20138.5)7 (6.8\u20139)0.15\u2003FDO2 (%)100 (80\u2013100)100 (80\u2013100)0.56Gas analysis\u2003PaO2 (mmHg)64 (51\u201378)82 (66\u2013109)0.007\u2003PaO2/FiO2 (mmHg)84 (73\u2013108)112 (83\u2013157)0.002\u2003PaCO2 (mmHg)44 (41\u201346)42 (36\u201349)0.27\u2003pH7.38 (7.35\u20137.43)7.38 (7.34\u20137.42)0.47Open in a separate windowData are expressed as number (%) or median [IQR]. Analyses were performed with the GraphPad Prism 6 software (San Diego, CA). All tests were two-tailed, with \u03b1 level at 0.05. The comparisons before vs. after prone position were realized by Wilcoxon matched-pairs signed-rank testRR respiratory rate, PEEP positive end-expiratory pressure, FiO2 fraction of inspired oxygen, PaCO2 arterial partial pressure of carbon dioxide, PaO2 arterial partial pressure of oxygen, FDO2 fraction on oxygen delivered in the sweep gas, ECMO extracorporeal membrane oxygenationTable 2Pre-ECMO characteristics, ventilator/ECMO settings, and outcomesAll patients (n\u00a0=\u200925)Prone ECMO (n\u00a0=\u200914)Supine ECMO (n\u00a0=\u200911)P valueAge (years)59 (49.5\u201363)59 (48\u201363)57 (48\u201366)0.82Male sex, n (%)22 (88)12 (85.7)10 (90.9)1Body mass index (kg/m2)32 (28.4\u201337.5)31.5 (28\u201338)33.6 (28.4\u201337.6)0.86Comorbidities\u2003Any, n (%)6 (24)3 (21.4)3 (27.3)1\u2003Hypertension, n (%)12 (48)6 (42.8)6 (54.5)0.7\u2003Diabetes, n (%)10 (40)5 (35.7)5 (45.4)0.7SAPS II60 (40\u201365)59.5 (46\u201362)61 (38\u201380)0.39Delay symptoms-ECMO (days)16 (11\u201318)15 (11\u201320)16 (10\u201316)0.94Delay mechanical ventilation-ECMO (days)7 (4\u201310)6.5 (4\u201310)7 (4\u201313)0.99Chest imaging (X-rays or CT)\u2003Consolidation, n (%)14 (56%)11 (78.6)3 (27.3)0.02\u2003Ground glass opacity, n (%)25 (100)14 (100)11 (100)\u2013\u2003Bilateral infiltration, n (%)25 (100)14 (100)11 (100)\u2013PaO2/FiO2 ratio before ECMO (mmHg)84 (69\u201398)84 (67\u201396)87 (66\u2013102)0.77Prone position before ECMO, n (%)25 (100)14 (100)11 (100)\u2013Neuromuscular blockers, n (%)25 (100)14 (100)11 (100)\u2013iNO before ECMO, n (%)21 (84)12 (85.7)9 (81.8)1Corticosteroids, n (%)4 (16)1 (7.1)3 (27.3)0.29MV and ECMO settings the first day of ECMO\u2003Tidal volume (mL/kg)2.6 (1.9\u20132.9)2.4 (1.7\u20133.1)2.6 (2.1\u20132.8)0.71\u2003Plateau airway pressure (cmH2O)26 (23\u201329)26 (25\u201329)26 (21\u201329)0.52\u2003PEEP (cmH2O)14 (11\u201320)14 (12\u201320)14 (10\u201320)0.47\u2003Driving pressure (cmH2O)10 (9\u201313)11 (10\u201314)9 (8\u201312)0.44\u2003Respiratory rate (cycles/min)14 (12\u201318)18 (13\u201325)12 (12\u201314)0.006\u2003Respiratory system compliance (mL/cmH2O)25 (15\u201332)24 (14\u201330)28 (18\u201333)0.36\u2003Inspired fraction of oxygen (%)50 (50\u201380)55 (50\u201372.5)50 (40\u201380)0.53\u2003ECMO blood flow (L/min)5.9 (5\u20136.3)5.8 (5.2\u20136.7)5.9 (4.9\u20136)0.31\u2003Sweep gas flow (L/min)5 (4\u20136)5.5 (4.5\u20136.2)4 (3.5\u20135)0.04\u2003Membrane lung fraction of oxygen (%)100 (80\u2013100)100 (80\u2013100)100 (90\u2013100)0.38Outcomes\u2003ECMO weaning, n (%)11 (44)3 (21.4)8 (72.7)0.02\u2003ECMO duration (days)10 (5\u201313)11 (6\u201313)6 (3\u201312)0.28\u200328-day mortality, n (%)14 (56)11 (78.6)3 (27.3)0.02\u2003Discharged alive from ICU, n (%)10 (40)2 (14.3)8 (72.7)0.005\u2003Still in ICU, n (%)1 (4)1 (7.1)01Open in a separate windowData are expressed as number (%) or median [IQR]. Analyses were performed with the GraphPad Prism 6 software (San Diego, CA). All tests were two-tailed, with \u03b1 level at 0.05. To compare the prone ECMO group to the supine ECMO group, we used the non-parametric Mann-Whitney test for continuous variables and the exact Fisher test for categorical onesSAPS II Simplified Acute Physiology Score, IQR interquartile range, CT computed tomography, PaO2 arterial partial pressure of oxygen, FiO2 fraction of inspired oxygen, PEEP positive end-expiratory pressure, ECMO extracorporeal membrane oxygenation, ICU intensive care unit DiscussionWe report that during VV-ECMO, PP improved oxygenation without a change in respiratory system compliance and PaCO2 at constant levels of minute ventilation and sweep gas flow. This does not suggest lung recruitment by PP but rather an optimization of ventilation and perfusion matching. Three explanations could be advanced for the mortality rate in the prone ECMO group (78.6%). First, prone ECMO patients may be more severe than supine ECMO patients. As described by Gattinoni et al., worsening patients progress from type 1 to type 2 (higher percentage of non-aerated tissue) [1], which is associated with a higher mortality rate [4]. Prone ECMO patients had much more consolidations, obviously because ECL was the main indication to be prone (n\u2009=\u200910/14). Furthermore, prone ECMO patients need a higher respiratory rate for a higher sweep gas flow suggesting that they may be exposed to a higher mechanical power, and they possibly had also a higher dead space. Second, postmortem biopsies, performed in 6 patients with ECL in the prone ECMO group, found a fibrin exudative presence both in the alveolar spaces and bronchioles followed by a fibroblastic phase [5] and raise the question of the use of corticosteroids (only one patient in the prone ECMO group). Third, as already described by Zeng et al. [6], more than half (8/11) of the patients died from septic shock and multiple organ failure, for which ECMO may be useless. ConclusionProne positioning under VV-ECMO improves oxygenation in SARS-CoV-2-induced ARDS without compromising the safety of the patients. The high mortality rate in prone ECMO patients may be explained by the greater illness severity and the lack of an immunomodulatory therapy such as corticosteroids. AcknowledgementsThe authors are indebted to thank the whole members of the Lille Intensive Care COVID-19 Group and the entire nursing staff of the intensive care unit of the \u201cRoger Salengro Hospital\u201d of the \u201cCentre Hospitalier Universitaire de Lille.\u201d.Lille Intensive Care COVID-19 group:Pauline Boddaert1 (Pauline.boddaert@chru-lille.fr), Arthur Durand1 (Arthur.durand@chru-lille.fr), Ahmed El Kalioubie1 (Ahmed.elkalioubie@chru-lille.fr), Patrick Girardie1 (Patrick.girardie@chru-lille.fr), Marion Houard1 (Marion.houard@chru-lille.fr), Geoffrey Ledoux1 (Geoffrey.ledoux@chru-lille.fr), Anne Sophie Moreau1 (Annesophie.moreau@chru-lille.fr), Christopher Niles1 (Christopher.niles@chru-lille.fr), Saad Nseir1 (Saad.nseir@chru-lille.fr), Thierry Onimus1 (Thierry.onimus@chru-lille.fr), Aurelia Toussaint1 (Aurelia.toussaint@chru-lille.fr), Sebastien Pr\u00e9au1 (Sebastien.preau@chru-lille.fr), Laurent Robriquet1 (Laurent.robriquet@chru-lille.fr), Anahita Rouze1 (Anahita.rouze@chru-lille.fr), Arthur Simonnet1 (Arthur.simonnet@chru-lille.fr), Sophie Six1 (Sophie.six@chru-lille.fr), Morgan Caplan1 (morgan.caplan@chru-lille.fr), Julien Goutay1 (julien.goutay@chru-lille.fr), Emmanuelle Jaillette1 (emmanuelle.jaillette@chru-lille.fr), Erika Parmentier-Decrucq1 (erika.decrucq@chru-lille.fr), Raphael Favory1 (raphael.favory@chru-lille.fr), Daniel Mathieu1 (daniel.mathieu@chru-lille.fr), Guillaume Degouy (Guillaume.degouy@chru-lille.fr), Mouhamed Moussa2 (Mouhamed.MOUSSA@CHRU-LILLE.FR)1P\u00f4le de R\u00e9animation, CHU Lille, University of Lille, F-59000 Lille, France2Service d\u2019Anesth\u00e9sie-R\u00e9animation Cardio-Vasculaire, CHU Lille, University of Lille, F-59000 Lille, France AbbreviationsARDSAcute respiratory distress syndromeICUIntensive care unitPPProne positioningVV-ECMOVeno-venous extracorporeal membrane oxygenationSARS-CoV-2Severe acute respiratory syndrome coronavirus 2FiO2Fraction of inspired oxygenPaO2Arterial partial pressure of oxygenFDO2Fraction on oxygen delivered in the sweep gasECLExtensive lung consolidation Authors\u2019 contributionsB.G and T.D. conceived the study. B.G, C.B., and N.C. collected the data. T.D. conducted the data analysis. B.G and T.D. drafted the manuscript. M.J. and J.P. revised the draft of the manuscript. All authors read and approved the final manuscript. FundingThis study was supported by the French government through the Programme Investissement d\u2019Avenir (I-SITE ULNE / ANR-16-IDEX-0004 ULNE) managed by the Agence Nationale de la Recherche (\"PHYSIO COVID\" and \"PREDICT\" projects) Availability of data and materialsThe datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Ethics approval and consent to participateFrench institutional authority for personal data protection (National Commission for Information Technology and Freedom, registration no DEC20-086) and ethics committee (ID-CRB 2020-A00763-36) approved the study. Consent for publicationNot applicable Competing interestsThe authors declare that they have no competing interests. FootnotesPublisher\u2019s NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Informationon behalf of the Lille Intensive Care COVID-19 group:Pauline Boddaert, Arthur Durand, Ahmed El Kalioubie, Patrick Girardie, Marion Houard, Geoffrey Ledoux, Anne Sophie Moreau, Christopher Niles, Saad Nseir, Thierry Onimus, Aurelia Toussaint, Sebastien Pr\u00e9au, Laurent Robriquet, Anahita Rouze, Arthur Simonnet, Sophie Six, Morgan Caplan, Julien Goutay, Emmanuelle Jaillette, Erika Parmentier-Decrucq, Raphael Favory, Daniel Mathieu, Guillaume Degouy, and  Mouhamed Moussa References1. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020;24(1):154. doi:\u00a010.1186/s13054-020-02880-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]2. Kimmoun A, Roche S, Bridey C, Vanhuyse F, Fay R, Girerd N, Mandry D, Levy B. Prolonged prone positioning under VV-ECMO is safe and improves oxygenation and respiratory compliance. Ann Intensive Care. 2015;5(1):35. doi:\u00a010.1186/s13613-015-0078-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]3. Papazian L, Aubron C, Brochard L, Chiche J-D, Combes A, Dreyfuss D, Forel JM, Gu\u00e9rin C, Jaber S, Mekontso-Dessap A, et al.  Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9:69. doi:\u00a010.1186/s13613-019-0540-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]4. Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PloS One. 2020;15(3):e0230548. doi:\u00a010.1371/journal.pone.0230548. [PMC free article] [PubMed] [CrossRef] [Google Scholar]5. Copin M-C, Parmentier E, Duburcq T, Poissy J, Mathieu D, Lille COVID-19 ICU and Anatomopathology Group. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 2020.46(6):1124-1126. [PMC free article] [PubMed]6. Zeng Y, Cai Z, Xianyu Y, Yang BX, Song T, Yan Q. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. Crit Care. 2020;24(1):148. doi:\u00a010.1186/s13054-020-2840-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]"}